TRUXIMA® CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML [SIN15671P]

Product Info

TRUXIMA® CONCENTRATE FOR SOLUTION FOR INFUSION 10MG/ML

[SIN15671P]

3.1 Therapeutic Indications
Truxima® is indicated for the treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin’s lymphomas.
Truxima® is indicated for the treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma (DLCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy.
Truxima® is indicated for the treatment of previously untreated patients with stage III–IV follicular lymphoma in combination with CVP chemotherapy.
Truxima® maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.

Chronic Lymphocytic Leukaemia
Truxima® is indicated in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL.

Rheumatoid Arthritis
Truxima® in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.

3.2 Dosage and Method of Administration
3.2.1 Standard Dosage
Truxima® should be administered as an i.v. infusion through a dedicated line, in an environment where full resuscitation facilities are immediately available, and under the close supervision of an experienced physician.
The prepared infusion solution must not be administered as an i.v. injection or bolus infusion.
Premedication consisting of an analgesic/antipyretic (e.g. paracetamol) and an antihistaminic drug (e.g. diphenhydramine) should always be administered before each infusion of Truxima®. Premedication with corticosteroids should also be considered.
Patients should be closely monitored for the onset of cytokine release syndrome (see section 3.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients who develop evidence of severe reactions, especially severe dyspnea, bronchospasm and hypoxia should have the infusion interrupted immediately. The patient should then be evaluated for evidence of tumour lysis syndrome including appropriate laboratory tests and, for pulmonary infiltration, with a chest x-ray. The infusion should not be restarted until complete resolution of all symptoms, and normalisation of laboratory values and chest x-ray findings. At this time, the infusion can be initially resumed at not more than one-half the previous rate. If the same severe adverse reactions occur for a second time the decision to stop the treatment should be seriously considered on a case by case basis.
Mild or moderate infusion-related reactions (see section 3.8 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) usually respond to a reduction in the rate of infusion. The infusion rate may be increased upon improvement of symptoms.

Low-grade or follicular non-Hodgkin’s lymphoma
Initial treatment
The recommended dosage of Truxima® used as monotherapy for adult patients is 375 mg/m² body surface area, administered as an i.v. infusion once weekly for 4 weeks.
The recommended dosage of Truxima® in combination with CVP chemotherapy is 375 mg/m² body surface area for 8 cycles (21 days/cycle), administered on day 1 of each chemotherapy cycle after IV administration of the corticosteroid component of CVP. Rituximab has shown acceptable safety in combination with other chemotherapies e.g. CHOP.

Re-treatment following relapse
Patients who have responded to rituximab initially have been treated again with rituximab at a dose of 375 mg/m² body surface area, administered as an i.v. infusion once weekly for 4 weeks (see Re-treatment, weekly for 4 doses – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Maintenance treatment
Previously untreated follicular lymphoma
The recommended dose of Truxima® used as a maintenance treatment for patients with previously untreated follicular lymphoma who have responded to induction treatment is: 375 mg/m² body surface area once every 2 months (starting 2 months after the last dose of induction therapy) until disease progression or for a maximum period of two years.

Relapsed/refractory follicular lymphoma
Patients who have responded to induction treatment may receive maintenance therapy with Truxima® given at 375 mg/m² body surface area once every 3 months until disease progression or for a maximum period of two years.

Diffuse large B-cell non-Hodgkin’s lymphoma
Truxima® should be used in combination with CHOP chemotherapy. The recommended dosage of Truxima® is 375 mg/m² body surface area, administered on day 1 of each chemotherapy cycle after i.v. administration of the corticosteroid component of CHOP. The other components of CHOP (cyclophosphamide, doxorubicin and vincristine) should be given after the administration of Truxima®. Safety and efficacy of rituximab have not been established in combination with other chemotherapies.

Chronic Lymphocytic Leukaemia
Prophylaxis with adequate hydration and administration of uricostatics starting 48 hours prior to start of therapy is recommended for CLL patients to reduce the risk of tumour lysis syndrome. For CLL patients whose lymphocyte counts are > 25 x10⁹/L it is recommended to administer prednisone/prednisolone 100 mg IV shortly before infusion with Truxima® to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome.
The dose for CLL is 375 mg/m² in the first cycle and 500 mg/m² in cycles 2–6, in combination with FC, administered every 28 days.

First infusion
The recommended initial infusion rate is 50 mg/h; subsequently, the rate can be escalated in 50 mg/h increments every 30 minutes to a maximum of 400 mg/h.

Subsequent infusions
Subsequent infusions of Truxima® can be started at a rate of 100 mg/h and increased by 100 mg/h increments every 30 minutes to a maximum of 400 mg/h.

Dosage adjustments during treatment
No dose reductions of Truxima® are recommended. When Truxima® is given in combination with CVP chemotherapy, standard dose reductions for the chemotherapeutic medicinal products should be applied.

Rheumatoid arthritis
A course of Truxima® consists of two 1000 mg i.v. infusions. The recommended dosage of Truxima® is 1000 mg by i.v. infusion followed two weeks later by the second 1000 mg i.v. infusion.
Patients may receive further courses of treatment, based on signs and symptoms of disease. In clinical studies, no patient received a second course of rituximab treatment within 16 weeks of the first infusion of the first course. The time interval between courses was variable, with the majority of patients receiving further therapy 6–12 months after the previous course. Some patients required even less frequent retreatment. The efficacy and safety of further courses is comparable to the first course. (See sections 3.8.2 and 4.1.2.3 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Rheumatoid arthritis patients should receive treatment with 100 mg i.v. methylprednisolone 30 minutes prior to Truxima® to decrease the rate and severity of acute infusion reactions (see section 3.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Dosage adjustments during treatment:
First infusion of each course:
The recommended initial rate for infusion is 50 mg/hr; after the first 30 minutes, it can be escalated in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
Second infusion of each course:
Subsequent doses of Truxima® IV can be infused at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30 minutes intervals, to a maximum of 400 mg/hr.

Rheumatoid Arthritis Only:
Alternative subsequent, faster, infusions schedule:
In RA, with a dose of 1000 mg Truxima®, if there are no infusion related reactions or other reasons to slow or cease the infusion, the standard infusion schedules shown above result in an estimated duration of infusion of 4h 15 minutes for the first infusion and 3h 15 minutes for the second infusion in each course.
If patients did not experience a serious infusion-related adverse event with their first or subsequent infusions of a dose of 1000 mg Truxima® administered over the standard infusion schedule, a more rapid infusion can be administered for second and subsequent infusions using the same concentration as in previous infusions (4 mg/ml in a 250 ml volume). Initiate at a rate of 250mg/hour for the first 30 minutes and then 600 mg/hour for the next 90 minutes. If the more rapid infusion is tolerated, this infusion schedule can be used when administering subsequent infusions. With this infusion schedule, the 1000 mg/250 ml infusion will generally be completed in 2 h.
Patients who have clinically significant cardiovascular disease including arrhythmias or previous serious infusion reactions to any prior biologic therapy or to rituximab, should not be administered the more rapid infusion.

Special Dosage Instructions
Pediatric use:
The safety and effectiveness of rituximab in pediatric patients (<18 years) have not been established. Hypogammaglobulinaemia has been observed in pediatric patients treated with rituximab, in some cases severe and requiring long-term immunoglobulin substitution therapy. The consequences of long term B cell depletion in pediatric patients are unknown.

3.3 Contraindications
Truxima® is contraindicated in patients with known hypersensitivity to rituximab, to any of its excipients or to murine proteins.
Active, severe infections.